Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | UQCRB | P14927 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | IDH2 | P48735 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17311796 | 0.92 | ALDH1A1 (0.70) | NAMPTALDH1A1RAB9ANPC1MEN1 | |
| SCHEMBL17311790 | 0.86 | MEN1 (0.73) | NAMPTALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL29767881 | 0.84 | UQCRB (0.64) | NAMPTALDH1A1POLBUQCRBLMNA | |
| SCHEMBL165317 | 0.84 | NAMPT (0.90) | NAMPT | |
| SCHEMBL12010876 | 0.83 | MEN1 (0.72) | NAMPTALDH1A1LMNAGAAMEN1 | |
| SCHEMBL164039 | 0.82 | NAMPT (0.73) | NAMPTRAB9ANPC1LMNAMEN1 | |
| SCHEMBL162432 | 0.80 | NAMPT (1.00) | NAMPT | |
| SCHEMBL12078328 | 0.80 | NAMPT (0.80) | NAMPTALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL12010902 | 0.80 | MEN1 (0.72) | NAMPTALDH1A1LMNAGAAMEN1 | |
| SCHEMBL10665495 | 0.80 | RAB9A (0.79) | NAMPTALDH1A1RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | NAMPT 596/4885ALDH1A1 592/4885POLB 4109/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | NAMPT 596/4885ALDH1A1 592/4885POLB 4109/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | NAMPT 596/4885ALDH1A1 592/4885POLB 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.